Mesoblast Limited (MESO)
NASDAQ: MESO · IEX Real-Time Price · USD
7.23
+0.13 (1.83%)
At close: Jul 19, 2024, 4:00 PM
7.30
+0.07 (0.97%)
Pre-market: Jul 22, 2024, 7:01 AM EDT

Mesoblast Statistics

Total Valuation

Mesoblast has a market cap or net worth of $825.11 million. The enterprise value is $869.56 million.

Market Cap 825.11M
Enterprise Value 869.56M

Important Dates

The next estimated earnings date is Wednesday, August 28, 2024, after market close.

Earnings Date Aug 28, 2024
Ex-Dividend Date n/a

Share Statistics

Mesoblast has 114.12 million shares outstanding.

Shares Outstanding 114.12M
Owned by Insiders (%) n/a
Owned by Institutions (%) 1.04%
Float n/a

Valuation Ratios

PE Ratio n/a
Forward PE 833.33
PS Ratio 113.76
Forward PS 21.84
PB Ratio 1.62
P/FCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales 119.89
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 2.72, with a Debt / Equity ratio of 0.24.

Current Ratio 2.72
Quick Ratio 2.60
Debt / Equity 0.24
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage -2.71

Financial Efficiency

Return on equity (ROE) is -14.50% and return on invested capital (ROIC) is -9.33%.

Return on Equity (ROE) -14.50%
Return on Assets (ROA) -10.90%
Return on Capital (ROIC) -9.33%
Revenue Per Employee $87,386
Profits Per Employee -$880,217
Employee Count 83
Asset Turnover 0.01
Inventory Turnover n/a

Taxes

Income Tax -188,000
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -23.89% in the last 52 weeks. The beta is 2.45, so Mesoblast's price volatility has been higher than the market average.

Beta (5Y) 2.45
52-Week Price Change -23.89%
50-Day Moving Average 7.34
200-Day Moving Average 4.06
Relative Strength Index (RSI) 49.07
Average Volume (20 Days) 173,745

Short Selling Information

Short Interest 460,516
Short Previous Month 470,849
Short % of Shares Out 1.14%
Short % of Float n/a
Short Ratio (days to cover) 2.91

Income Statement

In the last 12 months, Mesoblast had revenue of $7.25 million and -$73.06 million in losses. Loss per share was -$0.91.

Revenue 7.25M
Gross Profit 7.25M
Operating Income -58.88M
Pretax Income -73.25M
Net Income -73.06M
EBITDA n/a
EBIT -53.49M
Loss Per Share -$0.91
Full Income Statement

Balance Sheet

The company has $77.55 million in cash and $122.00 million in debt, giving a net cash position of -$44.45 million or -$0.39 per share.

Cash & Cash Equivalents 77.55M
Total Debt 122.00M
Net Cash -44.45M
Net Cash Per Share -$0.39
Equity (Book Value) 508.73M
Book Value Per Share 4.46
Working Capital 53.79M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$59.10 million and capital expenditures -$231,000, giving a free cash flow of -$59.33 million.

Operating Cash Flow -59.10M
Capital Expenditures -231,000
Free Cash Flow -59.33M
FCF Per Share -$0.73
Full Cash Flow Statement

Margins

Gross margin is 100.00%, with operating and profit margins of -811.75% and -1,007.28%.

Gross Margin 100.00%
Operating Margin -811.75%
Pretax Margin -1,009.87%
Profit Margin -1,007.28%
EBITDA Margin n/a
EBIT Margin -737.49%
FCF Margin -818.02%

Dividends & Yields

Mesoblast does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -25.17%
Shareholder Yield -25.17%
Earnings Yield -8.85%
FCF Yield -7.19%

Analyst Forecast

The average price target for Mesoblast is $7.00, which is -3.18% lower than the current price. The consensus rating is "Hold".

Price Target $7.00
Price Target Difference -3.18%
Analyst Consensus Hold
Analyst Count 6
Revenue Growth Forecast (5Y) 118.94%
EPS Growth Forecast (5Y) n/a
Stock Forecasts

Stock Splits

The last stock split was on January 10, 2024. It was a reverse split with a ratio of 1:2.

Last Split Date Jan 10, 2024
Split Type Reverse
Split Ratio 1:2

Scores

Mesoblast has an Altman Z-Score of 1.13 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score 1.13
Piotroski F-Score 2